Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a panel discussion titled, “Differentiation in Emerging Treatments for GA dAMD -- Perspectives From ISEE,” at the H.C. Wainwright 2^nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022, at 9:00 a.m. Eastern Time.

Investors and the general public are invited to access the live webcast of the panel discussion on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com. An archived replay of the on-demand presentation will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.

About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements

Any statements in this press release or made during the presentation referenced herein about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in the “Risk Factors” section of public filings made by Iveric Bio with the U.S. Securities and Exchange Commission. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release or the presentation, as applicable. Iveric Bio anticipates that subsequent events and developments may cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.

ISEE-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005782/en/

Investor Contact:

Kathy Galante

Senior Vice President, Investor Relations

kathy.galante@ivericbio.com

or

Media Contact:

Jeannie Neufeld

Senior Director, Public Relations and Communications

jeannie.neufeld@ivericbio.com

Source: IVERIC bio, Inc.